Reliance Life Sciences is upbeat on its biosimilars’ basket and is set to launch three products in the next one year. According to president and CEO KV Subramaniam, of the three products, one would be for stroke, a follicle stimulating hormone (for infertility), and interferon beta for multiple sclerosis.
“We already have products like GCSF, interferon, and erythropoietin in the market. Biosimilars is a huge opportunity as in India the market is about Rs 500 crore,” Subramaniam said on the sidelines of a CII pharmaceuticals summit.
He said that the company, which has about 150 scientists on board, is seeing a 100% growth year-on-year. It is also conducting trials in the area of stem cell therapy for the treatment of vitiligo, spinal cord injuries, Parkinson’s, diabetic ulcers, etc.
Comments